Co to je za nemoc a proč ji neléčíme?

prof. MUDr. Eva Králíková, CSc.,

Dermatol. praxi. 2019;13(1):3  

Treatment of moderate‑to‑severe

MUDr. Petra Brodská, Ph.D.

Dermatol. praxi. 2019;13(1):9-12 | DOI: 10.36290/der.2019.002  

Atopic dermatitis is a common, chronic, relapsing inflammatory skin disease. The complex of different interactions between individual genetic predisposition to atopic diseases (bronchial asthma, allergic rhino-conjunctivitis, and food or inhalant allergy), environmental factors, epidermal barrier dysfunction and abnormalities of the immune system are involved. The currently available therapeutics are limited. Over the last few years, new advances in the understanding of atopic dermatitis pathogenic mechanisms and inflammatory pathways have led to the identification of specific therapeutic targets and new molecules have been tested. Biological target...

How to examine and support microcirculation in pactients with diabetic foot

MUDr. Pavlína Piťhová, Ph.D.

Dermatol. praxi. 2019;13(1):14-19  

Diabetic foot syndrome is a debilitating diabetic complication. The treatment must be complex, containing offloading of theaffected foot, revascularization procedures in presence of ischemia, antibiotic treatment if infection is present, debridement andproper wound bed preparation and optimal wound care choice. It seems that the most important role in healing process playsfunctional microcirculation. In support of microcirculation we can use non-pharmacological (hyperbaric oxygenotherapy, localphysical treatments) and pharmacological methods as alprostadile or sulodexide.

Urticaria – review of disease and treatment, new antihistamine bilastin

MUDr. Jarmila Čelakovská, Ph.D.

Dermatol. praxi. 2019;13(1):21-24 | DOI: 10.36290/der.2019.004  

The aim of this article is to summarize the current knowledge about urticaria. This artile gives the review about the therapy withantihistamins, about their pharmacology and the proven efficacy and safety profile of bilastine, high selective antihistaminictreatment for H1 receptors in the management of urticaria.

Secukinumab in the treatment of severe form of psoriasis

MUDr. Jan Šternberský, Ph.D., MUDr. Martin Tichý, Ph.D.

Dermatol. praxi. 2019;13(1):26-28 | DOI: 10.36290/der.2019.005  

Secukinumab belongs to the type of treatment called biologics, products of biotechnological engineering. I tis fully humanizedantibody against interleukin 17A, which play one of the key roles in the pathogenesis of psoriasis. Secukinumab is indicated forthe treatment of severe forms of psoriasis, which are characterised by values of PASI > 10. Secukinumab has got very fast onsetof effect, excellent therapeutic response and up to date safety data are also very favorable. The case report describes excellenteffect of secukinumab in the treatment of severe form of psoriasis in an older man

Treatment pyoderma gangrenosum by topical tacrolimus

MUDr. Veronika Biolková, MUDr. Andrea Marešová

Dermatol. praxi. 2019;13(1):30-32 | DOI: 10.36290/der.2019.006  

Tacrolimus (Protopic ung) belongs to the group of topical immunomodulators. Its immunosupresive effect is used to treatmentmany diseases. Aim of this article is to specify its using in term of pyoderma gangrenosum.

Local treatment of different aetiology wounds

PhDr. Adéla Holubová, doc. PhDr. Andrea Pokorná, Ph.D.

Dermatol. praxi. 2019;13(1):49-52 | DOI: 10.36290/der.2019.021  

Specialized workplaces are taking care of a wide range of patients who come with different types of wounds and with different aetiology of wounds. The basis of wound management is the evaluation of the patient's overall condition, the local assessment of the non-healing wound and the surrounding tissues and last but not least also, the assessment of deeper tissue structures. Based on a comprehensive assessment and evaluation, a suitable material is selected and chosen to initiate local treatment with phase healing (also known as moist wound healing). In most cases, treatment is long-lasting and requires a change in the appropriate material according...

Výrazný efekt kožní pěny Enstilar® v porovnání se standardní léčbou aplikovanou na ostatní psoriatická ložiska
Seniorka s generalizovanou psoriázou

MUDr. Natálie Hlavinková

Dermatol. praxi. 2019;13(1):53-54  

Humira still has a lot to offer

MUDr. Miroslav Nečas, Ph.D.

Dermatol. praxi. 2019;13(1):34-44 | DOI: 10.36290/der.2019.020  

Humira has been on the market in the Czech Republic for 20 years in indications such as rheumatoid arthritis, Bechterev's disease or inflammatory bowel disease. For psoriasis treatment, Humira was registered in the Czech Republic in 2008 as one of the first biological preparations in this indication. Recent studies have also shown a very good adalimumab efficacy in specific and resistant forms of psoriasis, such as palmoplantar or nail psoriasis. Its indications have been extended in dermatological (hidradenitis suppurativa) and ophthalmological (uveitis) conditions as well as in some pediatric indications. Recent volume reduction in Humira injections...

Tofacitinib in treating psoriatic arthritis

MUDr. Hana Ciferská, Ph.D., MUDr. Jiří Štolfa

Dermatol. praxi. 2019;13(1):45-48 | DOI: 10.36290/der.2019.007  

The treatment of psoriatic arthritis (PsA) requires a multidisciplinary approach of a wide range of specializations in order to achieve remission, or at least a low activity of all disease manifestations, both musculoskeletal and dermal ones. Over the years, more therapeutic options have been developed allowing a more effective treatment in patients with a form of PsA particularly resistant to conventional therapy. Tofacitinib is a selective Janus kinase inhibitor whose efficacy and safety has been shown in a number of clinical trials of the OPAL programme in PsA. Data obtained from clinical trials have led to the introduction of tofacitinib in the...